{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:26:01Z","timestamp":1790641561953,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.leukres.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T21:03:28Z","timestamp":1371503008000},"page":"986-994","source":"Crossref","is-referenced-by-count":62,"title":["Fludarabine: A review of the clear benefits and potential harms"],"prefix":"10.1016","volume":"37","author":[{"given":"Joshua","family":"Lukenbill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.05.004_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0889-8588(18)30496-9","article-title":"Management of chronic lymphocytic leukemia","volume":"4","author":"Han","year":"1990","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2013.05.004_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0268-960X(93)90003-M","article-title":"Chronic lymphocytic leukaemia treatment","volume":"7","author":"Montserrat","year":"1993","journal-title":"Blood Rev"},{"key":"10.1016\/j.leukres.2013.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V50.6.1049.1049","article-title":"Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia","volume":"50","author":"Sawitsky","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0020","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N","article-title":"Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone","volume":"56","author":"Montserrat","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.1991.9.5.770","article-title":"Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial","volume":"9","author":"Raphael","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists\u2019 Collaborative Group","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2013.05.004_bib0035","first-page":"21","volume":"20","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0040","first-page":"1346","article-title":"Effectiveness of \u201cCHOP\u201d regimen in advanced untreated chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia","volume":"1","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2013.05.004_bib0045","first-page":"157","article-title":"Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia","volume":"2","author":"Keating","year":"1988","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.004_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0305-7372(77)80002-9","article-title":"Treatment of chronic lymphocytic leukemia","volume":"4","author":"Huguley","year":"1977","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.leukres.2013.05.004_bib0055","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/1097-0142(19860915)58:6<1185::AID-CNCR2820580602>3.0.CO;2-H","article-title":"Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial","volume":"58","author":"Keller","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0060","first-page":"457","article-title":"Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia","volume":"30","author":"Grever","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","article-title":"Fludarabine: a new agent with major activity against chronic lymphocytic leukemia","volume":"74","author":"Keating","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0070","first-page":"1135","article-title":"Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia","volume":"85","author":"Zinzani","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.05.004_bib0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.21554","article-title":"A retrospective comparison of three sequential groups of patients with recurrent\/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens","volume":"106","author":"Wierda","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0080","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01714952","article-title":"Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study","volume":"63","author":"Hiddemann","year":"1991","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0090","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent","volume":"81","author":"Keating","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0105","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0110","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.05.004_bib0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0120","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0125","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2013.05.004_bib0135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0140","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0145","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0150","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2013.05.004_bib0155","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.leukres.2013.05.004_bib0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00262285","article-title":"9-Beta-d-arabinofuranosyl-2-fluoroadenine 5\u2019-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma","volume":"18","author":"Danhauser","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0170","first-page":"700","article-title":"Proposed mechanism of therapeutic selectivity for 9-beta-d-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells","volume":"47","author":"Barrueco","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2013.05.004_bib0175","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1365-2141.2003.04336.x","article-title":"Mechanism of action of purine analogues in chronic lymphocytic leukaemia","volume":"121","author":"Pettitt","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0180","first-page":"2587","article-title":"Metabolism and therapeutic efficacy of 9-beta-d-arabinofuranosyl-2-fluoroadenine against murine leukemia P388","volume":"42","author":"Avramis","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2013.05.004_bib0185","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2006-05-023259","article-title":"Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal","volume":"108","author":"Moufarij","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0190","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.05.004_bib0195","first-page":"1731","article-title":"Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes","volume":"2","author":"Sandoval","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.05.004_bib0200","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403326","article-title":"Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine","volume":"18","author":"Morgan","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.004_bib0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20340","article-title":"Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia","volume":"79","author":"Lam","year":"2005","journal-title":"Am J Hematol"},{"issue":"September (13)","key":"10.1016\/j.leukres.2013.05.004_bib0215","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1182\/blood-2011-03-342485","article-title":"Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997","volume":"118","author":"Smith","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1081\/CNV-120005903","article-title":"The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study","volume":"20","author":"Lichtman","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1016\/j.leukres.2013.05.004_bib0225","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21151","article-title":"Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen","volume":"104","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0230","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0235","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/10428190310001624152","article-title":"Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory\/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study","volume":"45","author":"Kowal","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.05.004_bib0240","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.2830490207","article-title":"Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis","volume":"49","author":"Byrd","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdp297","article-title":"The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy","volume":"21","author":"Gill","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00280-002-0443-5","article-title":"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study","volume":"50","author":"Martell","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0260","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.22022","article-title":"The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders","volume":"107","author":"Polizzotto","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0265","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1182\/blood.V116.21.4637.4637","article-title":"Consequences of chemotherapy induced myelosuppression in patients with chronic lymphocytic leukemia (CLL)","volume":"116","author":"Lukenbill","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2141.1999.01379.x","article-title":"Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients","volume":"105","author":"Visani","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0275","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","article-title":"Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia","volume":"103","author":"Tournilhac","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0280","article-title":"Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation","author":"Waterman","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2013.05.004_bib0285","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.004_bib0290","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00277-005-1008-6","article-title":"Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment","volume":"84","author":"Lysak","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/scd.2005.14.3","article-title":"Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia","volume":"14","author":"Nichols","year":"2005","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.leukres.2013.05.004_bib0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.2000.01900.x","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0305","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.12585","article-title":"Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma","volume":"93","author":"Friedberg","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.05.004_bib0310","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1999.17.8.2454","article-title":"Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0315","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/leu.2008.167","article-title":"Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization","volume":"22","author":"Berger","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.004_bib0320","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V100.1.334","article-title":"Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide","volume":"100","author":"Eissner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0325","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.05.004_bib0330","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2006.06.0673","article-title":"Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia","volume":"24","author":"Kalaycio","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0335","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1399-0012.2007.00768.x","article-title":"Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy","volume":"22","author":"Laurenti","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.leukres.2013.05.004_bib0340","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0145-2126(00)00092-8","article-title":"Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma","volume":"25","author":"Misgeld","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.05.004_bib0345","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0350","first-page":"1546","article-title":"Treatment-related myelodysplasia following fludarabine combination chemotherapy","volume":"91","author":"Tam","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.05.004_bib0355","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0360","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2141.2006.06158.x","article-title":"High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders","volume":"134","author":"Bowcock","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0365","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1054\/bjoc.2000.1196","article-title":"Secondary myelodysplastic syndrome\/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma","volume":"83","author":"Saso","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0375","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.leu.2400816","article-title":"Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia","volume":"11","author":"O\u2019Brien","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.004_bib0380","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.leukres.2013.05.004_bib0385","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1517\/17425255.4.9.1217","article-title":"Pentostatin in chronic lymphocytic leukemia","volume":"4","author":"Sauter","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1989.7.4.433","article-title":"Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B","volume":"7","author":"Dillman","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0395","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.004_bib0400","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.25028","article-title":"Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia","volume":"116","author":"Kay","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0405","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0410","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s10637-011-9737-y","article-title":"A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia","volume":"30","author":"Reynolds","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.leukres.2013.05.004_bib0415","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.05.004_bib0420","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00280-002-0468-9","article-title":"Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment","volume":"50","author":"Lathia","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0425","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0430","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"September (13)","key":"10.1016\/j.leukres.2013.05.004_bib0440","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"February (5)","key":"10.1016\/j.leukres.2013.05.004_bib0445","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.004_bib0450","first-page":"1788","article-title":"Combination therapy with ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)","volume":"118","author":"Ferrajoli","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"March (3)","key":"10.1016\/j.leukres.2013.05.004_bib0455","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2011.047324","article-title":"Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach","volume":"97","author":"Stephens","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.05.004_bib0460","first-page":"983","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): follow-up of a phase Ib\/II study","volume":"118","author":"O\u2019Brien","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.leukres.2013.05.004_bib0465","first-page":"6508","article-title":"Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): interim results of a phase Ib\/II study","volume":"29","author":"Byrd","year":"2011","journal-title":"ASCO Meeting Abstracts 2011"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T14:15:14Z","timestamp":1715523314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0145212613001537"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.05.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}